Why Peptide Manufacturers Cannot Grant Distribution Rights — And the Correct Agreement Framework
The phrase "distribution agreement" is almost always the wrong framework for a peptide business. A Red/Yellow/Green field guide and the five correct agreement types — with draft templates available to AEG Members.
Most peptide business operators have encountered a manufacturer or supplier at some point offering something along these lines: "We can set up a distribution agreement — you'll have exclusive rights to our products in your region."
It sounds like a serious business relationship. It sounds like the kind of thing that creates value and competitive protection.
It is, legally speaking, a red flag.
This post explains why "distribution agreement" is almost always the wrong framework for a peptide business relationship — and what the correct legal structures actually look like. It includes a concrete Red/Yellow/Green field guide with real examples you can use to evaluate your own operation.
The Core Problem With "Distribution Rights" in the Peptide Context
The word "distribution" implies a familiar chain: a manufacturer makes a product → a distributor buys that product → the distributor resells it to customers → title transfers, warehousing occurs, the product sits on a shelf somewhere.
That model exists in pharmaceuticals. It does not exist — legally — in the way most peptide businesses operate.
The reason: In most cases, the peptides being discussed in a peptide business context are compounded peptides — not FDA-approved drug products. They are made by pharmacies (either 503A compounding pharmacies or 503B outsourcing facilities) pursuant to specific prescriptions or for specific clinical purposes. When a pharmacy compounds a peptide, it is providing a service: the act of preparing a patient-specific medication. The pharmacy is not manufacturing an approved drug product that can then be distributed through a wholesale chain.
If a peptide manufacturer were to grant true distribution rights, the peptide would need to be an FDA-approved drug product with an NDA or BLA. None of those conditions are met in the typical peptide business relationship. The result: when operators sign what they believe is a distribution agreement, they are signing a document that describes a legal relationship that does not actually exist.
The Actual Legal Frameworks That Apply
What operators need are agreements that accurately describe the relationships that actually exist.